Medindia

X

Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting

Thursday, September 17, 2009 General News J E 4
Advertisement
BOSTON, Sept. 16 The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes convention center in Boston. The three-day meeting serves as a forum for heart failure specialists to present research findings and advances in treatment and addresses emerging trends in research and new developments in the approach to treating heart failure patients. Four late breaking trials were presented today:



"These four late breaking clinical trials highlight some of the interesting innovations in heart failure treatment," said Dr. Douglas Mann, HFSA President. "We are proud to have such important trials unveiled during the annual meeting."



For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility.



About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.



About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,500 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.





-- Clinical and prognostic value of Galectin-3, a novel fibrosis-associated biomarker, in patients with chronic heart failure. This trial concluded that GAL-3 is a powerful novel marker with incremental value for outcome stratification in patients with chronic HF which is independent of the severity of HF as reflected by plasma BNP levels. -- Relationship of resting myocardial perfusion to death and hospitalization in heart failure patients: results from the nuclear sub-study of the HF-ACTION trial. This nuclear substudy of the HF-ACTION trial provided unique information regarding the prognostic significance of variables derived from gated SPEC MPI and the potential role of resting perfusion defects in predicting adverse outcomes in HF patients with reduced LV EF from a large, recently completed prospective clinical trial. -- Renoprotective and potassium sparing effects of low dose dopamine in acute decompensated heart failure. This trial hypothesized that low-dose dopamine exerts renoprotective and potassium sparing effects when administered in patients with ADHF. It concluded that the combination of low dose furosemide and dopamine achieves equally effective diuresis but reduced renal and electrolyte complication rates as compared to high dose furosemide infusion. Larger studies are needed to confirm these findings and elucidate the effects of dopamine on renal function in ADHF patients. -- MARVEL-1: A double-blind, randomized, controlled multicenter study to assess the safety and cardiovascular effects of Myocell implantation by a catheter delivery system in congestive heart failure patients post myocardial infarction(s). MARVEL-1 was the first double-blind placebo controlled study to assess intramyocardial myoblast administration using a percutaneous approach in patients with advanced ventricular dysfunction. A relatively high arrhythmic event rate was observed, but was short lived. Clinical meaningful trends in improvements in 6-MWT compared with placebo administration were observed. Given the limited treatment options in these patients, myoblast therapy warrants continued evaluation. These results will impact the design of future studies in this field.

SOURCE The Heart Failure Society of America
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Indian Stem Cell Trial to Broaden Diabetic Foot In...
S
Avaxia Biologics Awarded Phase I SBIR Grant to Dev...